<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">FEMS Microbiol Lett</journal-id><journal-id journal-id-type="iso-abbrev">FEMS Microbiol. Lett</journal-id><journal-id journal-id-type="publisher-id">femsle</journal-id><journal-title-group><journal-title>FEMS Microbiology Letters</journal-title></journal-title-group><issn pub-type="ppub">0378-1097</issn><issn pub-type="epub">1574-6968</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6322438</article-id><article-id pub-id-type="doi">10.1093/femsle/fny291</article-id><article-id pub-id-type="publisher-id">fny291</article-id><article-categories><subj-group subj-group-type="heading"><subject>Minireview</subject><subj-group subj-group-type="category-toc-heading"><subject>Biotechnology and Synthetic Biology</subject></subj-group></subj-group><subj-group subj-group-type="category-oup-series"><subject>Mini Review</subject></subj-group></article-categories><title-group><article-title>Genome editing of lactic acid bacteria: opportunities for food, feed, pharma and biotech</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>B&#x000f6;rner</surname><given-names>Rosa A</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kandasamy</surname><given-names>Vijayalakshmi</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Axelsen</surname><given-names>Amalie M</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Nielsen</surname><given-names>Alex T</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6189-7753</contrib-id><name><surname>Bosma</surname><given-names>Elleke F</given-names></name><!--<email>elfebo@biosustain.dtu.dk</email>--><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1">The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet B220, 2800 Kongens Lyngby, Denmark</aff><author-notes><corresp id="cor1"><bold>Corresponding author</bold>: The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet B220, 2800 Kongens Lyngby, Denmark. Tel: +4593511710; Fax: not available; E-mail: <email>elfebo@biosustain.dtu.dk</email></corresp></author-notes><pub-date pub-type="epub" iso-8601-date="2018-12-18"><day>18</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>12</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>366</volume><issue>1</issue><elocation-id>fny291</elocation-id><history><date date-type="received"><day>27</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; FEMS 2018.</copyright-statement><copyright-year>2019</copyright-year><license license-type="cc-by" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="fny291.pdf"/><abstract><title>Abstract</title><p>This mini-review provides a perspective of traditional, emerging and future applications of lactic acid bacteria (LAB) and how genome editing tools can be used to overcome current challenges in all these applications. It also describes available tools and how these can be further developed, and takes current legislation into account. Genome editing tools are necessary for the construction of strains for new applications and products, but can also play a crucial role in traditional ones, such as food and probiotics, as a research tool for gaining mechanistic insights and discovering new properties. Traditionally, recombinant DNA techniques for LAB have strongly focused on being food-grade, but they lack speed and the number of genetically tractable strains is still rather limited. Further tool development will enable rapid construction of multiple mutants or mutant libraries on a genomic level in a wide variety of LAB strains. We also propose an iterative Design&#x02013;Build&#x02013;Test&#x02013;Learn workflow cycle for LAB cell factory development based on systems biology, with &#x02018;cell factory&#x02019; expanding beyond its traditional meaning of production strains and making use of genome editing tools to advance LAB understanding, applications and strain development.</p></abstract><abstract abstract-type="teaser"><p>Traditional, emerging and future applications of lactic acid bacteria can all benefit from genome editing and a proposed Design&#x02013;Build&#x02013;Test&#x02013;Learn workflow cycle for advancement of strain development.</p></abstract><kwd-group kwd-group-type="keywords"><kwd>genetic tool development</kwd><kwd>food fermentation</kwd><kwd>biotherapeutics</kwd><kwd>phytotherapeutics</kwd><kwd>synthetic biology</kwd><kwd>GMO regulation</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">Marine Biotechnology</named-content></funding-source><award-id>5178&#x02013;00003B</award-id></award-group></funding-group><counts><page-count count="12"/></counts></article-meta></front><body><sec sec-type="intro" id="sec1"><title>INTRODUCTION</title><p>Lactic acid bacteria (LAB) are a phylogenetically diverse but functionally related group of bacteria comprising the families <italic>Aerococcaceae</italic>, <italic>Carnobacteriaceae</italic>, <italic>Enterococcaceae</italic>, <italic>Lactobacillaceae</italic>, <italic>Leuconostocaceae</italic> and <italic>Streptococcaceae</italic>. They are low-GC, Gram-positive, facultatively anaerobic, non-sporulating bacteria and have a highly fermentative lifestyle, converting a range of sugars into mainly lactic acid. LAB have a long history in different forms of food-related biotechnology and are gaining attention towards novel uses due to their safety for human and animal consumption, metabolic versatility and wide ecological niche adaptation (including industrial-scale fermentations) (Fig. <xref ref-type="fig" rid="fig1">1</xref>).</p><fig id="fig1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Overview of traditional, emerging and future applications of LAB with the most important contributions of genome editing tools for each, including current regulatory requirements. For all applications, genome editing provides the possibility to make tailored design strains with desired properties, but the direct use of GMO strains is currently limited; here we have depicted only possibilities within the current legislation. *For food ingredients and enzymes: mostly non-GMO via self-cloning. **Currently not approved, but GMOs are needed to reach the desired application.</p></caption><graphic xlink:href="fny291fig1"/></fig><p>Genome editing tools for LAB are limited compared to species like <italic>Saccharomyces cerevisiae</italic> and <italic>Escherichia coli</italic>, mostly due to restrictive legislations, and poor consumer acceptance of genetically modified organisms (GMOs) in food. Although LAB were a pioneer group studied for development of genetic tools, with many cloning vectors derived from them still routinely used (De Vos <xref rid="bib121" ref-type="bibr">2011</xref>), their tools have mainly focused on being food-grade and less on generating many mutants in a short time. Furthermore, laboratory evolution and random mutagenesis have been widely applied for strain improvement in food applications, as strains resulting from these methods are considered non-GMO. However, such methods do not result in targeted modifications and selection of the right strains is often laborious, despite bioinformatics being highly instrumental to narrow down the initial strain selection (Walsh <italic>et&#x000a0;al.</italic><xref rid="bib124" ref-type="bibr">2017</xref>). The expansion of LAB genome editing tools with a focus on speed to enable fast, clean, targeted and stable genomic modifications for a wide variety of strains is crucial for both fundamental studies and applications.</p><p>In this mini-review, we provide a perspective of traditional, emerging and future applications of LAB and how genome editing can advance all these LAB fields, regardless the strain's GMO-status in the final application (Fig. <xref ref-type="fig" rid="fig1">1</xref>). Furthermore, we discuss available tools and suggest how these can be further developed to enable or advance all these applications and fundamental studies, taking also current legislation into account. Finally, we propose an iterative Design&#x02013;Build&#x02013;Test&#x02013;Learn workflow cycle based on systems biology, similar to what is currently used for industrial production platform strains (Palsson <xref rid="bib88" ref-type="bibr">2015</xref>; Campbell, Xia and Nielsen <xref rid="bib21" ref-type="bibr">2017</xref>). The focus is on engineering single/pure strains and not on microbial community engineering, which has recently been reviewed elsewhere (Sheth <italic>et&#x000a0;al.</italic><xref rid="bib108" ref-type="bibr">2016</xref>; Bober, Beisel and Nair <xref rid="bib10" ref-type="bibr">2018</xref>; Zerfa&#x000df;, Chen and Soyer <xref rid="bib131" ref-type="bibr">2018</xref>).</p></sec><sec id="sec2"><title>APPLICATIONS OF LAB AND THE CONTRIBUTION OF GENOME EDITING</title><sec id="sec2-1"><title>Food fermentations</title><p>Fermentation of food and beverages has been carried out for thousands of years (10<monospace>&#x000a0;</monospace>000 BC), most likely for food preservation (Prajapati and Nair <xref rid="bib98" ref-type="bibr">2003</xref>). The most recent trends in using LAB for food are related to improving properties like nutritional value (e.g. vitamin production), organoleptic quality (e.g. flavour formation) or technofunctionalities (e.g. polysaccharide formation). LAB are also key in primary processing of ingredients such as cocoa and coffee beans (De Vuyst and Weckx <xref rid="bib122" ref-type="bibr">2016</xref>; Pereira, Soccol and Soccol <xref rid="bib91" ref-type="bibr">2016</xref>) and significantly influence the final product quality (see also <italic>Agro-applications</italic>). With the longest commercial use and an estimated market growth of 7.2% for the next five years (Mordor Intelligence <xref rid="bib50" ref-type="bibr">2018</xref>), fermented food is one of the most important economical applications of LAB.</p><p>A primary strategy for research in food applications is screening microbial collections (Bourdichon <italic>et al</italic>. <xref rid="bib13" ref-type="bibr">2012</xref>). However, with global access to microbial and genetic diversity now limited by the Nagoya Protocol and uncertainties about its interpretation (Darajati <italic>et&#x000a0;al.</italic><xref rid="bib29" ref-type="bibr">2013</xref>; Johansen <xref rid="bib54" ref-type="bibr">2017</xref>), achieving genetic variation through genomic manipulation gains relevance. Due to poor consumer acceptance of GMOs, and restrictive legislation, strain development for food applications mainly relies on untargeted and laborious methods based on evolution (Derkx <italic>et al</italic>. <xref rid="bib31" ref-type="bibr">2014</xref>; Bachmann <italic>et al</italic>. <xref rid="bib5" ref-type="bibr">2015</xref>; Johansen <xref rid="bib55" ref-type="bibr">2018</xref>), or on targeted but limited non-GMO methods (Zeidan <italic>et al</italic>. <xref rid="bib130" ref-type="bibr">2017</xref>) (see GMO vs non-GMO).</p><p>Nevertheless, even without the final GMO-strain ending up in the product, food applications can benefit from genome editing as a research tool (Fig. <xref ref-type="fig" rid="fig1">1</xref>). For example, targeted mutagenesis can be applied to predicted genes for a certain trait to evaluate their function and phenotype (Derkx <italic>et al</italic>. <xref rid="bib31" ref-type="bibr">2014</xref>). This is especially important for compounds of which the production is not yet fully understood, such as expolysaccharides (Zeidan <italic>et&#x000a0;al.</italic><xref rid="bib130" ref-type="bibr">2017</xref>). It can also aid in guiding more targeted selection and reduced screening size to select for naturally evolved strains towards the desired modification(s), such as was shown for phage-resistance factor <italic>YjaE</italic> in <italic>Lactococcus lactis</italic> (Stuer-Lauridsen and Janzen <xref rid="bib113" ref-type="bibr">2006</xref>). Altogether, improved understanding of compound formation and microbial metabolism will aid in more rational and accelerated efforts to achieve superior properties in food products. Advancing genome editing methods for a wide variety of strains will enable for example screening of mutant libraries, which will further accelerate these processes.</p></sec><sec id="sec2-2"><title>Probiotics</title><p>The World Health Organisation (WHO) has defined probiotics as live organisms that, when administered in adequate amounts, confer a health benefit on the host. Especially <italic>Lactobacillus</italic> species have attracted attention as probiotics, which are used as adjuvant or prophylaxis against many different diseases (Reid <xref rid="bib103" ref-type="bibr">2017</xref>; Mays and Nair <xref rid="bib73" ref-type="bibr">2018</xref>), as well as in a range of animal husbandries (Syngai <italic>et al</italic>. <xref rid="bib116" ref-type="bibr">2016</xref>). The market for probiotics is ever-expanding, with a projected world-wide size of $46.55 billion by 2020 (Salvetti and O&#x02019;Toole <xref rid="bib105" ref-type="bibr">2017</xref>). Nevertheless, the complex molecular mechanistics of modes of action of both probiotics and LAB&#x02013;host&#x02013;pathogen interactions are poorly understood (Lebeer <italic>et al</italic>. <xref rid="bib64" ref-type="bibr">2018</xref>).</p><p>After implementation of EU legislation on health claims in 2009, no probiotics have been granted the right to claim health benefits in the EU. A vast amount of scientific literature indicates beneficial effects of probiotics, but so far in all cases the European Food and Safety Authority (EFSA) considered the scientific substantiation insufficient and rejected all health claims (Dronkers <italic>et al</italic>. <xref rid="bib32" ref-type="bibr">2018</xref>). The most important aspects for this are the lack of molecular and mechanistic knowledge of probiotic modes of action<italic/>, irreproducibility of trials, as well as strong individual responses of the hosts, and strain-specificity (Glanville <italic>et&#x000a0;al.</italic><xref rid="bib44" ref-type="bibr">2015</xref>; Salvetti and O&#x02019;Toole <xref rid="bib105" ref-type="bibr">2017</xref>; van Pijkeren and Barrangou <xref rid="bib94" ref-type="bibr">2017</xref>).</p><p>Improving molecular insight into the (dis)functionality of probiotics and observed strain-specificity will be instrumental in achieving the right to health claims and hence further secure markets. Although genomics-, transcriptomics- and metabolomics-based studies are valuable tools (also termed &#x02018;probiogenomics&#x02019; in this context) (Guinane, Crispie and Cotter <xref rid="bib46" ref-type="bibr">2016</xref>) for identification of potential biomarkers, combining these with genome editing can provide molecular mechanistic insight (Fig. <xref ref-type="fig" rid="fig1">1</xref>) (Lebeer <italic>et al</italic>. <xref rid="bib64" ref-type="bibr">2018</xref>). Similar to food, GMOs are not allowed in probiotics, and despite a few examples (Bron <italic>et al</italic>. <xref rid="bib17" ref-type="bibr">2007</xref>; Lebeer <italic>et al</italic>. <xref rid="bib64" ref-type="bibr">2018</xref>), using GMOs/genome editing as research tool is still relatively underexploited. Advancing genome editing tools to be less time-consuming and more suitable for rapid screening (with suitable fast readout methods) and applicable to a larger number of strains, would potentially enable identification of novel, unpredicted factors. Furthermore, once regulations allow, genome editing could be used to create GMO-/improved probiotics that could for example be combined with biotherapeutics (van Pijkeren and Barrangou <xref rid="bib94" ref-type="bibr">2017</xref>).</p></sec><sec id="sec2-3"><title>Industrial production platforms for green chemicals, fuels and enzymes</title><p>A wide range of products can be made through bio-based production via microbial fermentation of biomass-derived sugars to replace fossil resources, such as (building blocks for) plastics, nylons, solvents, fuels, pharmaceuticals and food and cosmetic ingredients. Traditional work horses for this type of cell factories are <italic>E. coli</italic> and <italic>S. cerevisiae</italic>, mostly because their genetic tools are well-developed and their metabolism is relatively well-understood. LAB are gaining interest as alternative hosts for many reasons, which have been extensively reviewed elsewhere (Gaspar <italic>et&#x000a0;al.</italic><xref rid="bib43" ref-type="bibr">2013</xref>; Boguta <italic>et&#x000a0;al.</italic><xref rid="bib11" ref-type="bibr">2014</xref>; Mazzoli <italic>et al</italic>. <xref rid="bib74" ref-type="bibr">2014</xref>; Bosma, Forster and Nielsen <xref rid="bib12" ref-type="bibr">2017</xref>; Sauer <italic>et al</italic>. <xref rid="bib106" ref-type="bibr">2017</xref>; Hatti-Kaul <xref rid="bib47" ref-type="bibr">2018</xref>).</p><p>One main advantage of LAB is their food-grade safety and adaptation to food-related environments, enabling their use as production platforms in food-related processes. A recent example is the use of metabolically engineered <italic>L. lactis</italic> for ethanol production from lactose in whey, showcasing an alternative of waste valorisation in cheese-making (Liu <italic>et&#x000a0;al.</italic><xref rid="bib67" ref-type="bibr">2016</xref>). Attempts have been made to ferment the whey-lactose with yeasts, but these suffer from low robustness and slow fermentation; using <italic>L. lactis</italic> proved a promising solution on which the company Alcowhey was founded (Liu <italic>et al</italic>. <xref rid="bib67" ref-type="bibr">2016</xref>; Jensen <italic>et&#x000a0;al.</italic><xref rid="bib51" ref-type="bibr">2017</xref>). Another LAB-suitable application would be the in-process production of proteins or enzymes for food products by starter or adjunct strains (Matthews <italic>et&#x000a0;al.</italic><xref rid="bib72" ref-type="bibr">2004</xref>). LAB enzymes are also employed for production of food-grade speciality chemicals, pharmaceutical intermediates and nutraceuticals, mostly as whole cell catalysts (Hatti-Kaul <xref rid="bib47" ref-type="bibr">2018</xref>). Cofactor regeneration is a challenge in such processes but ingenious solutions using natural substrates have been employed as source of reducing equivalents (Perna <italic>et&#x000a0;al.</italic><xref rid="bib92" ref-type="bibr">2016</xref>).</p><p>Except for <italic>L. lactis</italic>, no extensive metabolic engineering has been performed to obtain economically competitive LAB platform organisms (Gaspar <italic>et&#x000a0;al.</italic><xref rid="bib43" ref-type="bibr">2013</xref>; Mazzoli <italic>et&#x000a0;al.</italic><xref rid="bib74" ref-type="bibr">2014</xref>; Bosma, Forster and Nielsen <xref rid="bib12" ref-type="bibr">2017</xref>; Sauer <italic>et&#x000a0;al.</italic><xref rid="bib106" ref-type="bibr">2017</xref>). This is largely due to underdeveloped genome editing tools for industrially relevant strains. For example, many <italic>Lactobacillus</italic> and <italic>Pediococcus</italic> spp. have been shown to be more tolerant to several stresses compared to <italic>L. lactis</italic>, but lack widely applicable high-throughput genetic tools (Boguta <italic>et&#x000a0;al.</italic><xref rid="bib11" ref-type="bibr">2014</xref>; Bosma, Forster and Nielsen <xref rid="bib12" ref-type="bibr">2017</xref>). Advancing tools for such organisms is important to make use of the wide variety of LAB and their metabolic capacities.</p></sec><sec id="sec2-4"><title>Agro-applications</title><p>To feed the ever-growing world population, crop health is crucial. The use of pesticides is increasingly regarded as undesired, creating the need for organic solutions. Traditionally, research on plant health-promoting microorganisms has focused on Rhizobia, <italic>Bacillus</italic> and <italic>Pseudomonas</italic>; LAB also form a part of the phytomicrobiome of several plant species, but have yet been underexplored (Axel <italic>et&#x000a0;al.</italic><xref rid="bib4" ref-type="bibr">2012</xref>; Lamont <italic>et&#x000a0;al.</italic><xref rid="bib61" ref-type="bibr">2017</xref>). Examples of LAB biocontrol activities are production of reactive oxygen species, bacteriocins (see <italic>Biotherapeutics</italic>), competitive colonisation (overgrowing pathogens) and alteration of the plant immune response (Gajbhiye and Kapadnis <xref rid="bib41" ref-type="bibr">2016</xref>; Konappa <italic>et&#x000a0;al.</italic><xref rid="bib58" ref-type="bibr">2016</xref>; Lamont <italic>et&#x000a0;al.</italic><xref rid="bib61" ref-type="bibr">2017</xref>). In many cases, the identity of the antimicrobial compound and which genes encode for it is unknown. Moreover, little is known about the molecular interactions between LAB and plants. Similar to described above for probiotics, genome editing will aid in increasing understanding, which will lead to new possibilities for biocontrol and improvement of plant growth and health (Lamont <italic>et&#x000a0;al.</italic><xref rid="bib61" ref-type="bibr">2017</xref>), expanding LAB to a type of plant probiotics.</p><p>Moreover, plant health is related to food and feed for organoleptic and technofunctional properties in the final product. The presence of LAB in the phytomicrobiome has shown to influence for example the processes and tastes of sourdough fermentation of durum wheat flour (Minervini <italic>et&#x000a0;al.</italic><xref rid="bib78" ref-type="bibr">2015</xref>) and milk derived from silage-fed cows (Kala&#x0010d; <xref rid="bib56" ref-type="bibr">2011</xref>). A better understanding of the dynamics of the phytomicrobiome in raw material and food processing could guide new applications or technofunctionalities in the food industry.</p><p>Altogether, the agro-industry is a promising LAB application field and whereas the use of GMOs in organic farming is currently out of the question, genome editing can be beneficial as a research tool (Fig. <xref ref-type="fig" rid="fig1">1</xref>).</p></sec><sec id="sec2-5"><title>Biotherapeutics</title><p>One of the most promising novel applications of LAB is their medical use in therapeutics, prevention and diagnosis (Mays and Nair <xref rid="bib73" ref-type="bibr">2018</xref>). Especially their use as delivery agents of drugs and vaccines is gaining attention. LAB are particularly suitable as they are already generally recognised health-improving agents and safe for human consumption. Efforts using LAB as biotherapeutics have mostly focused on gastrointestinal tract-related ailments using the strains as oral vectors, leveraging their capacity to survive stomach acids and adhere to the intestinal epithelium (De Moreno De Leblanc <italic>et&#x000a0;al.</italic><xref rid="bib79" ref-type="bibr">2015</xref>; Hwang <italic>et&#x000a0;al.</italic><xref rid="bib48" ref-type="bibr">2016</xref>; Carvalho <italic>et&#x000a0;al.</italic><xref rid="bib22" ref-type="bibr">2017</xref>; Durrer, Allen and Hunt von Herbing <xref rid="bib35" ref-type="bibr">2017</xref>). LAB are also being developed for mucosal (vagina and mouth) delivery of molecules and as vaccines (Wang <italic>et&#x000a0;al.</italic><xref rid="bib125" ref-type="bibr">2016</xref>), as well as for wound treatment (V&#x000e5;gesj&#x000f6; <italic>et&#x000a0;al.</italic><xref rid="bib123" ref-type="bibr">2018</xref>). Many LAB naturally produce antimicrobial peptides (e.g. bacteriocins), which are currently commercialised in the purified form for veterinary use (Ahmad <italic>et&#x000a0;al.</italic><xref rid="bib1" ref-type="bibr">2017</xref>). These compounds have demonstrated high specificity and potency <italic>in vivo</italic>; they are a potential alternative to fight the rising antimicrobial resistance, and also have applications in food preservation and probiotics (Yang <italic>et&#x000a0;al.</italic><xref rid="bib129" ref-type="bibr">2014</xref>; Mathur <italic>et al</italic>. <xref rid="bib71" ref-type="bibr">2017</xref>). Targeted delivery via synthetic biology can potentiate their use as antimicrobial agents of the future. Also, CRISPR-based antimicrobials hold great promise (Pursey <italic>et&#x000a0;al.</italic><xref rid="bib99" ref-type="bibr">2018</xref>) and would be highly interesting to develop also using LAB. Another attractive field is the use of LAB for diagnosis by acting as biosensors inside or outside of the body (Lubkowicz <italic>et&#x000a0;al.</italic><xref rid="bib69" ref-type="bibr">2018</xref>).</p><p>The microbial therapeutics and diagnostics market is estimated to occupy close to 79% of the therapeutics segment by 2030 with annual growths over 80% from 2019 onwards, attracting boosts in funding and investment (Microbiome Therapeutics and Diagnostics Market (2nd Edition), 2017&#x02013;2030 2017). As a new field, there are no commercially available LAB-biotherapeutics yet, besides the non-GMO ones composing the community in human faecal transplantations approved by the FDA (FDA <xref rid="bib39" ref-type="bibr">2016</xref>). This is expected to change soon, as the first clinical trials by pharmaceutical companies with live-engineered biotherapeutics are on-going (Bron and Kleerebezem <xref rid="bib15" ref-type="bibr">2018</xref>). Although more research is required regarding efficiency, fundamental questions and safety, LAB as biotherapeutics can bring a revolution in personalised and precise medicine (Mays and Nair <xref rid="bib73" ref-type="bibr">2018</xref>).</p><p>Stable and tuneable modifications via genome editing and synthetic biology are crucial in this field for the addition of the therapeutic compounds to the microbial delivery host, as well as for the insertion of regulation mechanisms, delivery strategies and biocontainment systems (Mays and Nair <xref rid="bib73" ref-type="bibr">2018</xref>) (Fig. <xref ref-type="fig" rid="fig1">1</xref>). The absence of genetic markers, such as antibiotics, in the final strain is essential to avoid risk of transferring antibiotic resistance to pathogens inhabiting the host. Furthermore, the current tools are mostly limited to a few strains (<italic>L. lactis</italic>) while several <italic>Lactobacillus</italic> spp. have proven a more promising target group due to prolonged survival and colonisation of the gastrointestinal tract. Currently, their limited genetic accessibility and toolbox restrain their use (Allain <italic>et&#x000a0;al.</italic><xref rid="bib2" ref-type="bibr">2015</xref>; van Pijkeren and Barrangou <xref rid="bib94" ref-type="bibr">2017</xref>; Bron and Kleerebezem <xref rid="bib15" ref-type="bibr">2018</xref>). Finally, as with probiotics, better understanding of the interactions with the host on a molecular and cellular level is needed to enable full development of LAB as biotherapeutics (Fig. <xref ref-type="fig" rid="fig1">1</xref>) (van Pijkeren and Barrangou <xref rid="bib94" ref-type="bibr">2017</xref>).</p></sec></sec><sec id="sec3"><title>OVERVIEW OF LAB GENOME EDITING TOOLS: CURRENT AND FUTURE</title><p>Several methods have been developed for making genomic modifications in LAB, including food-grade ones that result in strains labelled as non-GMO (see also GMO vs non-GMO). These are still very useful for the many LAB applications where GMOs are not allowed, and continue to gain interest (Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>). However, to further expand LAB applications as described above, the following advancements are required: (i) increase editing speed, (ii) methods for multiplexing (i.e. simultaneous modification of several genomic loci in one editing round) and (iii) broaden the range of strains that can be transformed and edited. This section discusses how these can be achieved via existing methods and future developments, following the different steps of the editing process from transformation to mutant construction (Fig. <xref ref-type="fig" rid="fig2">2</xref>). We focus on methods that can be targeted to any desired place in the genome with stable and marker-free results. Also, screening/readout systems for the generated mutants are required, but as this is a field in itself and out of the scope of this review, the reader is referred to other recent publications (Chen <italic>et&#x000a0;al.</italic><xref rid="bib24" ref-type="bibr">2017</xref>; Duarte, Barbier and Schaerli <xref rid="bib33" ref-type="bibr">2017</xref>; Emanuel, Moffitt and Zhuang <xref rid="bib38" ref-type="bibr">2017</xref>; Longwell, Labanieh and Cochran <xref rid="bib68" ref-type="bibr">2017</xref>).</p><fig id="fig2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Schematic overview of transformation and genome editing methods currently available for LAB. Only methods that result in clean mutations (or silencing) and that can be targeted to any desired site in the genome are shown. The grey arrow on the chromosomes represents the target gene of interest. Abbreviations: Chr.: chromosome; str.: strand; AB<sub>R</sub>: antibiotic resistance; ssDNA: single stranded DNA; dsDNA: double stranded DNA; gRNA: guide RNA, which can be either a single guide (sgRNA) or a dual crRNA:tracrRNA. <bold>(</bold><bold>A</bold><bold>)</bold>, Transformation methods. For electroporation/chemical/heat shock transformation, the yellow flash indicates any of these external treatments (electrical pulse, chemical treatment or heat shock). For the protoplast-based method, the left arrow indicates protoplast fusion of two different cells and the right arrow indicates transformation of protoplasts. <bold>(</bold><bold>B</bold><bold>)</bold>, Integration/homologous recombination (HR) methods. <italic>Plasmid-based HR</italic> uses the native recombination machinery. dsDNA <italic>recombineering</italic> requires the expression of a phage &#x003bb;- or Rac prophage-derived exonuclease (Exo or RecE) and an ssDNA binding protein (Beta or RecT), whereas ssDNA recombineering only requires the single-stranded binding protein. In the case of the &#x003bb;-Red system, also Gam can be added, which inhibits host DNA exonucleases (Van Pijkeren and Britton <xref rid="bib96" ref-type="bibr">2012</xref>; Pines <italic>et al</italic>. <xref rid="bib97" ref-type="bibr">2015</xref>). A marker can be introduced within the homologous regions but this does not result in clean mutations. Without marker insertion (as depicted here), the result can be either wild-type or mutant, which need to be verified by PCR, and for which Cas9 can be used as <italic>counter-selection</italic> as depicted in C. <bold>(</bold><bold>C</bold><bold>)</bold>, CRISPR-Cas-based editing and silencing tools. The two methods on the left could be used in combination with any of the integration methods shown in B. For endogenous systems, a type II system is depicted here with Cas9 as effector molecule, but also other endogenous systems could be used for both editing and silencing, although this has not yet been shown in LAB (Luo <italic>et&#x000a0;al.</italic><xref rid="bib70" ref-type="bibr">2015</xref>; Rath <italic>et al</italic>. <xref rid="bib101" ref-type="bibr">2015</xref>; Li <italic>et al</italic>. <xref rid="bib66" ref-type="bibr">2016</xref>). <italic>Repurposing endogenous systems</italic> to target the organism's own genome can be achieved by plasmid-based expression of the native minimal CRISPR array (leader and two repeats), or a synthetic single guide RNA based on the native system, together with desired spacer(s) to target a (or multiple) gene(s) of interest. Prerequisites are that the native system is active under the <italic>in vivo</italic> editing conditions and that the different components and the PAM recognised by the system are characterised (Crawley <italic>et&#x000a0;al.</italic><xref rid="bib26" ref-type="bibr">2018</xref>). <italic>Gene silencing</italic> using catalytically inactive Cas9 (&#x02018;dead&#x02019; Cas9, dCas) has only been shown as proof of principle in <italic>L. lactis</italic> (Berlec <italic>et&#x000a0;al.</italic><xref rid="bib7" ref-type="bibr">2018</xref>) but the tuneable nature has not yet been exploited in LAB, but several methods for this are available and have been shown in other organisms (Mougiakos <italic>et&#x000a0;al.</italic><xref rid="bib81" ref-type="bibr">2016</xref>).</p></caption><graphic xlink:href="fny291fig2"/></fig><sec id="sec3-1"><title>Transformation (DNA transfer) and genetic accessibility</title><p>Transformation (the process to introduce DNA) is the critical first step towards any genome editing and can be achieved via naturally occurring or artificial methods (Fig. <xref ref-type="fig" rid="fig2">2</xref>A). Natural methods, particularly conjugation, have been exploited to achieve non-GMO LAB strains (Pedersen <italic>et&#x000a0;al.</italic><xref rid="bib90" ref-type="bibr">2005</xref>; Derkx <italic>et&#x000a0;al.</italic><xref rid="bib31" ref-type="bibr">2014</xref>; Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>). Conjugative plasmids and transposons are very common in LAB, but the details of conjugative mechanisms are not fully understood and this field needs improvement to widen its applicability (Kullen and Klaenhammer <xref rid="bib60" ref-type="bibr">2000</xref>; Dahmane <italic>et&#x000a0;al.</italic><xref rid="bib28" ref-type="bibr">2017</xref>; Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>). Phage transduction is a wide-spread phenomenon in LAB but not yet frequently harnessed for targeted DNA exchange (Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>). It also is a potential tool for human microbiome engineering (Sheth <italic>et&#x000a0;al.</italic><xref rid="bib108" ref-type="bibr">2016</xref>). Natural competence, in which exogenous DNA translocates through a native DNA uptake machinery, is well-known in <italic>Streptococcus</italic> (Gardan <italic>et&#x000a0;al.</italic><xref rid="bib42" ref-type="bibr">2009</xref>; Muschiol <italic>et&#x000a0;al.</italic><xref rid="bib84" ref-type="bibr">2015</xref>), but only recently identified and achieved in <italic>Lactococcus</italic> (David <italic>et&#x000a0;al.</italic><xref rid="bib30" ref-type="bibr">2017</xref>; Mulder <italic>et&#x000a0;al.</italic><xref rid="bib83" ref-type="bibr">2017</xref>). The abundance of natural competence is likely underestimated (Blokesch <xref rid="bib9" ref-type="bibr">2016</xref>; Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>) and the new findings might pave the way for natural transformation in other LAB that are so far considered non-genetically accessible.</p><p>In artificial methods, cells need to be made competent through for example washing with cell envelope-weakening solutions, after which external agents are used for cell permeabilisation and transformation. Electroporation is the most suitable method for high-throughput purposes due to its simplicity, efficiency and wide applicability (Landete <xref rid="bib62" ref-type="bibr">2017</xref>). Generalised electroporation protocols have been successfully used to transform a wide range of LAB strains. Although these studies indicate that the majority of LAB is genetically accessible through electroporation, efficiencies varied strongly among strains and protocols need to be optimised (Landete <italic>et&#x000a0;al.</italic><xref rid="bib63" ref-type="bibr">2014</xref>; Bosma, Forster and Nielsen <xref rid="bib12" ref-type="bibr">2017</xref>). A method with low efficiencies and less suitable for targeted modification but suitable for the large-scale exchange of genomic DNA for e.g. evolutionary engineering via genome shuffling, is protoplast fusion (Mercenier and Chassy <xref rid="bib76" ref-type="bibr">1988</xref>; Patnaik <italic>et&#x000a0;al.</italic><xref rid="bib89" ref-type="bibr">2002</xref>).</p><p>Bacteria, including LAB, have evolved defence strategies against foreign DNA, such as restriction modification (RM) and CRISPR-Cas systems or combinations thereof (Dupuis <italic>et al</italic>. <xref rid="bib34" ref-type="bibr">2013</xref>). In RM-systems, a set of enzymes discriminates self from non-self DNA by methylating it and cleaving the invading DNA (Vasu and Nagaraja <xref rid="bib118" ref-type="bibr">2013</xref>). Recent reports have shown the existence of &#x02018;phase-variable&#x02019; RM-systems in LAB, which result in variable methylation patterns (De Ste Croix <italic>et&#x000a0;al.</italic><xref rid="bib111" ref-type="bibr">2017</xref>), and as of yet ununderstood restriction-like factors that mutate during the editing process (Ortiz-Velez <italic>et&#x000a0;al.</italic><xref rid="bib87" ref-type="bibr">2018</xref>). Limitations for introducing and maintaining foreign DNA have been mainly related to RM-systems and to further develop any genome editing method, it is often required to bypass these (Teresa Alegre, Carmen Rodr&#x000ed;guez and Mesas <xref rid="bib117" ref-type="bibr">2004</xref>; Spath, Heinl and Grabherr <xref rid="bib110" ref-type="bibr">2012</xref>; Joergensen <italic>et&#x000a0;al.</italic><xref rid="bib53" ref-type="bibr">2013</xref>).</p></sec><sec id="sec3-2"><title>Genome editing (DNA integration)</title><p>Detailed descriptions of traditional and currently available LAB genome editing methods are provided in several recent reviews (Bosma, Forster and Nielsen <xref rid="bib12" ref-type="bibr">2017</xref>; Landete <xref rid="bib62" ref-type="bibr">2017</xref>; Hatti-Kaul <xref rid="bib47" ref-type="bibr">2018</xref>). Here, we outline the main steps and bottlenecks in LAB genome editing and focus on how recent advancements can be further developed to improve this. Classically, LAB genome editing for targeted genomic modifications is based on integrative plasmids to insert or remove a gene of interest via two crossover events using the cells&#x02019; native recombination machinery (Fig. <xref ref-type="fig" rid="fig2">2</xref>B). Steps in this procedure that can be time-consuming are the selection of integrants (i.e. cells that have correctly integrated the exogenous DNA over the homologous regions) and the curing of the integrative plasmid after homologous recombination (HR). Several tools have traditionally been used to make these processes more efficient, such as thermo-sensitive and suicide vectors and counter-selectable markers. Instead, the more recently developed method of recombineering enables direct integration of linear ssDNA or dsDNA oligos into the genome with the help of phage-derived recombination systems (Fig. <xref ref-type="fig" rid="fig2">2</xref>B). This avoids curing integrative plasmids from the cells and cloning of HR regions, making this method more suitable for high-throughput purposes. However, recombineering requires identification of phage-derived proteins and optimisation of the system for each new strain, and hence has been developed for less strains than plasmid-based systems. Recombineering has been established in <italic>Lactococcus lactis</italic>, <italic>Lactobacillus reuteri</italic>, <italic>Lactobacillus gasseri</italic> (Van Pijkeren and Britton <xref rid="bib96" ref-type="bibr">2012</xref>), <italic>Lactobacillus casei</italic> (Xin <italic>et&#x000a0;al.</italic><xref rid="bib127" ref-type="bibr">2018</xref>) and <italic>Lactobacillus plantarum</italic> (Yang, Wang and Qi <xref rid="bib128" ref-type="bibr">2015</xref>; Leenay <italic>et&#x000a0;al.</italic><xref rid="bib65" ref-type="bibr">2018</xref>). Also, site-specific recombination systems based on phage integrases and phage attachment sites have been developed for LAB, often as food-grade systems (Alvarez, Herrero and Su&#x000e1;rez <xref rid="bib3" ref-type="bibr">1998</xref>; Br&#x000f8;ndsted and Hammer <xref rid="bib19" ref-type="bibr">1999</xref>; Grath, van Sinderen and Fitzgerald <xref rid="bib45" ref-type="bibr">2002</xref>). Although these systems are very valuable and applicable to a wide range of strains for stable integrations, we will not go into detail here as they are limited to integrations into specific locations in the genome (i.e. in the phage attachment sites only).</p><p>For both plasmid-based and recombineering methods, a critical bottleneck step is the selection of correctly edited mutants. Plasmid-based editing can result in either mutants or wild-type revertants (Fig. <xref ref-type="fig" rid="fig2">2</xref>B), and recombineering efficiencies are inherently low, resulting in large amounts of wild-type cells: for ssDNA recombineering in <italic>L. reuteri</italic>, efficiency was 0.4%&#x02013;19% (Pijkeren and Britton <xref rid="bib95" ref-type="bibr">2014</xref>). This creates an often laborious and time-consuming PCR-based screening process. Marker insertion-and-removal systems such as Cre-<italic>lox</italic> have been employed in some LAB to overcome this, but such methods leave small scars and hence are not fully clean (Yang, Wang and Qi <xref rid="bib128" ref-type="bibr">2015</xref>; Xin <italic>et al</italic>. <xref rid="bib127" ref-type="bibr">2018</xref>). To increase efficiencies of clean editing systems, it is necessary to establish selection tools for mutants, or counter-selection tools against wild-types. Most recently, CRISPR-Cas9-technology has proven a powerful counter-selection tool in bacteria (Fig. <xref ref-type="fig" rid="fig2">2</xref>C) and to significantly speed up and advance engineering (Mougiakos <italic>et&#x000a0;al.</italic><xref rid="bib81" ref-type="bibr">2016</xref>, <xref rid="bib80" ref-type="bibr">2018</xref>).</p></sec><sec id="sec3-3"><title>CRISPR-Cas-based genome editing</title><p>CRISPR-Cas systems in nature function as prokaryotic adaptive immune systems (Barrangou <italic>et&#x000a0;al.</italic><xref rid="bib6" ref-type="bibr">2007</xref>; Brouns <italic>et&#x000a0;al.</italic><xref rid="bib18" ref-type="bibr">2008</xref>) and although a wide variety exists (Koonin, Makarova and Zhang <xref rid="bib59" ref-type="bibr">2017</xref>), Cas9&#x02014;the endonuclease of Type II CRISPR-Cas systems&#x02014;has gained most fame as a versatile genome editing tool. When directed to its target DNA by a provided guide RNA and recognising its target next to a short DNA motif called protospacer adjacent motif (PAM), Cas9 creates blunt dsDNA breaks (Fig. <xref ref-type="fig" rid="fig2">2</xref>C). Whereas eukaryotes can repair such breaks by non-homologous end joining (NHEJ), this system is absent or inactive in most bacteria (Bowater and Doherty <xref rid="bib14" ref-type="bibr">2006</xref>). Hence, they are unable to repair Cas9-induced breaks, which creates a powerful counter-selection tool against wild-type cells as these will be killed due to Cas9 cleavage (Fig. <xref ref-type="fig" rid="fig2">2</xref>C) (Mougiakos <italic>et al</italic>. <xref rid="bib81" ref-type="bibr">2016</xref>). In <italic>L. reuteri</italic>, Cas9-based selection of mutants after ssDNA recombineering increased the efficiency from 0.4%&#x02013;19% to 100% (Oh and Van Pijkeren <xref rid="bib86" ref-type="bibr">2014</xref>). Cas9-based editing has now been established in <italic>L. reuteri</italic> together with ssDNA recombineering (Oh and Van Pijkeren <xref rid="bib86" ref-type="bibr">2014</xref>), in <italic>L. plantarum</italic> with dsDNA recombineering and plasmid-based HR (Leenay <italic>et al</italic>. <xref rid="bib65" ref-type="bibr">2018</xref>), and with plasmid-based HR in <italic>L. lactis</italic> (van der Els <italic>et&#x000a0;al.</italic><xref rid="bib37" ref-type="bibr">2018</xref>). Cas9 has also been used for removal of large mobile genetic elements in <italic>Streptococcus thermophilus</italic> (Selle, Klaenhammer and Barrangou <xref rid="bib107" ref-type="bibr">2015</xref>) and <italic>L. lactis</italic> (van der Els <italic>et&#x000a0;al.</italic><xref rid="bib37" ref-type="bibr">2018</xref>).</p><p>A major challenge of using Cas9 in bacteria is that its activity must be tightly controlled to allow HR-based genome editing before killing wild-type cells, requiring tightly controllable expression systems or multiple plasmids and transformation rounds. A nickase-variant of Cas9 makes single stranded nicks instead of double stranded breaks due to a mutation in one of the two active sites of Cas9. These nicks are less lethal, and are furthermore suggested to enhance HR (Song <italic>et al</italic>. <xref rid="bib109" ref-type="bibr">2017</xref>). The nickase was used together with an integrative plasmid in <italic>L. casei</italic> with an efficiency up to 65%, requiring only a single transformation round (Song <italic>et&#x000a0;al.</italic><xref rid="bib109" ref-type="bibr">2017</xref>).</p><p>Establishing HR/Cas9-based editing methods is not trivial due to strong and yet ununderstood strain-specific differences. A direct comparison of recombineering- and plasmid-based methods in <italic>L. plantarum</italic> showed several strain-specific differences in efficiencies (Leenay <italic>et al</italic>. <xref rid="bib65" ref-type="bibr">2018</xref>). Moreover, Cas9 has shown to be toxic in certain bacteria, for which subsequently alternative CRISPR-Cas systems such as Cas12a (formerly Cpf1) have been successful (Jiang <italic>et&#x000a0;al.</italic><xref rid="bib52" ref-type="bibr">2017</xref>). Several alternative Cas9s and other CRISPR-Cas-systems are now being characterised for genome editing in other microorganisms, showing advantages such as wider applicability, specificity, stability or less toxicity (Jiang <italic>et al</italic>. <xref rid="bib52" ref-type="bibr">2017</xref>; Mougiakos <italic>et al</italic>. <xref rid="bib82" ref-type="bibr">2017</xref>; Nakade, Yamamoto and Sakuma <xref rid="bib85" ref-type="bibr">2017</xref>). Evaluating such alternative systems in LAB might open new possibilities for CRISPR-Cas-based editing in a wider range of LAB. Furthermore, the repurposing of endogenous CRISPR-Cas systems, which are abundantly present in LAB (Sun <italic>et al</italic>. <xref rid="bib114" ref-type="bibr">2015</xref>), into counter-selection systems is a promising recent approach for broadening the number of engineerable species (Fig. <xref ref-type="fig" rid="fig2">2</xref>C) (Crawley <italic>et&#x000a0;al.</italic><xref rid="bib26" ref-type="bibr">2018</xref>).</p><p>All reported genome modifications in LAB so far only make one modification at a time, while multiplexing would be crucial for many applications including fundamental studies. Multiplexing is complicated with plasmid-based HR and would strongly benefit from establishing recombineering methods for more strains. Another interesting option in this regard is the recently developed base editing, in which a catalytically impaired Cas9-variant is coupled to a cytidine deaminase that does not make DNA breaks, but C to T (or G to A) substitutions (Kim <italic>et&#x000a0;al.</italic><xref rid="bib57" ref-type="bibr">2017</xref>). This can be used to make targeted point mutations to create premature stop codons and inactivate genes without the need for HR. It has only been used in few bacteria (Kim <italic>et&#x000a0;al.</italic><xref rid="bib57" ref-type="bibr">2017</xref>; Eid, Alshareef and Mahfouz <xref rid="bib36" ref-type="bibr">2018</xref>; Zheng <italic>et&#x000a0;al.</italic><xref rid="bib132" ref-type="bibr">2018</xref>) and not yet for LAB.</p></sec><sec id="sec3-4"><title>Gene silencing and synthetic biology</title><p>A catalytically &#x02018;dead&#x02019; Cas9-variant (dCas9) can be used for high-throughput and tuneable gene silencing instead of gene editing: mutating both Cas9-active sites creates a catalytically inactive Cas9 that binds DNA but does not cleave it (Bikard <italic>et&#x000a0;al.</italic><xref rid="bib8" ref-type="bibr">2013</xref>; Qi <italic>et&#x000a0;al.</italic><xref rid="bib100" ref-type="bibr">2013</xref>). This has not been exploited for LAB other than as proof of principle in <italic>L. lactis</italic> (Berlec <italic>et&#x000a0;al.</italic><xref rid="bib7" ref-type="bibr">2018</xref>) and would be a highly valuable addition to the toolbox. No HR is needed, creating an easy screening tool with high potential for multiplexing. Although not yet used for this purpose in LAB, its tuneable nature creates a powerful tool for investigating downregulation of essential genes (Fig. <xref ref-type="fig" rid="fig2">2</xref>C) (Peters <italic>et&#x000a0;al.</italic><xref rid="bib93" ref-type="bibr">2016</xref>; Mougiakos <italic>et&#x000a0;al.</italic><xref rid="bib80" ref-type="bibr">2018</xref>; Rousset <italic>et&#x000a0;al.</italic><xref rid="bib104" ref-type="bibr">2018</xref>).</p><p>Regarding synthetic biology developments, improving regulatory control systems is highly desirable, especially for bio-therapeutic applications. Particularly, promoters that can be induced in e.g. the gut by the host metabolites to control gene expression <italic>in vivo</italic> at the targeted location (Bober, Beisel and Nair <xref rid="bib10" ref-type="bibr">2018</xref>), as well as bio-containment strategies, which are crucial for safety (Wegmann <italic>et&#x000a0;al.</italic><xref rid="bib126" ref-type="bibr">2017</xref>). Systems based on quorum-sensing or reciprocal transcriptional repression systems have been used for inducing autolysis in <italic>E. coli</italic> (Chan <italic>et&#x000a0;al.</italic><xref rid="bib23" ref-type="bibr">2016</xref>; Hwang <italic>et&#x000a0;al.</italic><xref rid="bib49" ref-type="bibr">2017</xref>) and could be adapted to LAB. Gene circuits construction is also important for the development of bacterial biosensors, where engineered strains can detect certain molecules related to a disease in the human host.</p></sec><sec id="sec3-5"><title>GMO vs non-GMO</title><p>Regulations surrounding GMOs are complex and consumer acceptance plays an important role in the reluctance to use GMOs, especially in food. In the EU, GMOs are not allowed in the final product (i.e. as food, probiotics or bio- and phytotherapeutics), but are allowed as contained production hosts (i.e. as producers of chemicals, fuels and enzymes in which the organism remains within a factory/reactor) (Johansen <xref rid="bib55" ref-type="bibr">2018</xref>). Even if the microorganism does not end up in the final product but is used to produce food ingredients (e.g. enzymes), lack of consumer acceptance of GMO-products puts pressure on food and also ingredient companies to use GMO-free enzymes (Derkx <italic>et&#x000a0;al.</italic><xref rid="bib31" ref-type="bibr">2014</xref>). Therefore, even contained microorganisms in such cases should be non-GMO.</p><p>For these reasons, genome editing tools for LAB traditionally focus on systems labelled as non-GMO. Next to strains created via random mutagenesis or laboratory evolution, the current EU legislation considers strains generated by natural gene transfer methods (e.g. conjugation; transduction) as non-GMO, provided none of the involved strains is a GMO (Sybesma <italic>et&#x000a0;al.</italic><xref rid="bib115" ref-type="bibr">2006</xref>; Johansen <xref rid="bib54" ref-type="bibr">2017</xref>). For contained use, microorganisms are also considered non-GMO if they are made by &#x02018;self-cloning,&#x02019; which means modification of a strain with DNA taken from the strain itself or from a very close relative. This may involve recombinant vectors as long as these consist of DNA from this same or closely related strain (Meacher <xref rid="bib75" ref-type="bibr">2000</xref>; Verstrepen, Chambers and Pretorius <xref rid="bib119" ref-type="bibr">2006</xref>; Landete <xref rid="bib62" ref-type="bibr">2017</xref>). By definition, this also means that clean deletion mutants created with such LAB-vectors are considered non-GMO (De Vos <xref rid="bib120" ref-type="bibr">1999</xref>). Self-cloning and its &#x02018;non-GMO&#x02019; label is only allowed for contained use and the organisms created by such methods are not allowed in the final product (Sybesma <italic>et&#x000a0;al.</italic><xref rid="bib115" ref-type="bibr">2006</xref>; Johansen <xref rid="bib55" ref-type="bibr">2018</xref>), or should be inactivated at the end of the process.</p><p>Regarding advanced genome editing tools (e.g. recombineering; CRISPR-Cas), if the tool vectors come from species related to the target strain, they could be considered as &#x02018;self-cloning,&#x02019; having the added advantage of being clean/marker-free if using appropriate methods (Fig. <xref ref-type="fig" rid="fig2">2</xref>). Targeted genomic modifications would result in a similar genotype as the wild-type strain, plus or minus a specific gene that could also have been edited by a classical method like random mutagenesis (Johansen <xref rid="bib54" ref-type="bibr">2017</xref>). It has been argued by several players in the field that it is questionable whether a strain obtained via random mutagenesis (currently allowed for human consumption) is safer than if that same strain was obtained via targeted and clean self-cloning methods (Johansen <xref rid="bib54" ref-type="bibr">2017</xref>; Bron <italic>et&#x000a0;al.</italic><xref rid="bib16" ref-type="bibr">2019</xref>). However, the EU-court has recently ruled against allowing such new genome editing methods (including CRISPR-Cas) as &#x02018;non-GMO,&#x02019; whereas in the USA Cas9-edited plants have recently been allowed (Callaway <xref rid="bib20" ref-type="bibr">2018</xref>; Court of Justice of the European Union <xref rid="bib25" ref-type="bibr">2018</xref>). This does not change the current situation, but it does mean that allowance of any form of non-contained GMOs, including via clean methods, is unlikely in the near future in the EU. Nevertheless, information dissemination for public awareness and further investigation of potential long-term effects of GMOs is still needed (Sybesma <italic>et&#x000a0;al.</italic><xref rid="bib115" ref-type="bibr">2006</xref>; Fears and Ter Meulen <xref rid="bib40" ref-type="bibr">2017</xref>; Johansen <xref rid="bib54" ref-type="bibr">2017</xref>; Csutak and Sarbu <xref rid="bib27" ref-type="bibr">2018</xref>).</p></sec></sec><sec id="sec4"><title>CONCLUSIONS AND OUTLOOK</title><p>In the long term, genome editing could be used to create tailored LAB strains for properties on demand for any given application. This is currently done for e.g. production platforms. For more traditional applications related to human consumption, this possibility is restrained by regulations and consumer opinion. Nevertheless, genome editing can be applied for strain advancement in an indirect way as a research tool, by improving knowledge on the strain itself and the relations with its hosts, as well as provide guidance towards targets for modifications using &#x02018;natural&#x02019; or accepted editing methods avoiding a GMO label. To enable such developments, more advanced genome editing tools need to be developed, for a wider range of LAB. This includes making more strains genetically accessible for transformation and establishing recombineering and CRISPR-Cas-based methods, including multiplex genome editing and silencing.</p><p>For all applications described here, whether the final strain is a GMO or not, the LAB can be considered as microbial cell factories, and an iterative Design&#x02013;Build&#x02013;Test&#x02013;Learn workflow could be applied similar to that used in the development of traditional industrial biotechnology strains for green chemical production (e.g. <italic>E. coli; S. cerevisiae</italic>) (Palsson <xref rid="bib88" ref-type="bibr">2015</xref>) (Fig. <xref ref-type="fig" rid="fig3">3</xref>). Such a systems biology-based workflow has been shown to significantly speed up the process of cell factory development by combining genome editing and synthetic biology, <italic>in silico</italic> prediction and models, and high-throughput methods/automation (Campbell, Xia and Nielsen <xref rid="bib21" ref-type="bibr">2017</xref>). To be applied to the wide variety of LAB applications described here, this workflow could be used as in a classical metabolic engineering approach, generating GMO or non-GMO strains depending on the modification method used, but also as a research tool for fundamental understanding of the strains by designing mechanistically targeted experiments with non-GMOs as final result (Figs <xref ref-type="fig" rid="fig1">1</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Accelerated methods for strain construction, selection and screening/readout tools are crucial for advancing this strategy. Also, expanding and improving genome-scale metabolic models is needed to strengthen the <italic>in silico</italic> part (Stefanovic, Fitzgerald and McAuliffe <xref rid="bib112" ref-type="bibr">2017</xref>; Rau and Zeidan <xref rid="bib102" ref-type="bibr">2018</xref>). An ever-increasing interest in LAB and the advances in genome editing and biotechnological developments will undoubtedly provide breakthrough solutions for innovation in the wide and ever-expanding applications of LAB.</p><fig id="fig3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Iterative Design&#x02013;Build&#x02013;Test&#x02013;Learn workflow for cell factory development. Proposed workflow generally applicable to all forms of cell factories discussed in this review based on systems biology for rational and advanced strain development. Adapted for LAB from the &#x02018;classical&#x02019; industrial workflow described elsewhere (Palsson <xref rid="bib88" ref-type="bibr">2015</xref>; Campbell, Xia and Nielsen <xref rid="bib21" ref-type="bibr">2017</xref>). In a full cycle, strains that pass through <italic>Build</italic> are manipulated by genome editing methods that result in GMO or non-GMO strains (see GMO vs non-GMO). For targeted engineering, the desired genotypes are planned in the <italic>Design</italic> step. The same workflow can be applied to a collection of strains where no genetic modification is performed, but rather goes directly to experimental screening (<italic>Test</italic>). In this case, <italic>in silico</italic> work can aid in the pre-selection of the strains to be tested experimentally based on genomic information (<italic>Design</italic>). This can also be a second cycle after a first one which included genome editing to determine targets. In all cases, experimental data analysis and computer integration on e.g. genome scale models (<italic>Learn</italic>) will bring information that can be used for planning and designing the next iterative cycle. *In the EU, self-cloning is allowed for contained use, but not for non-contained applications such as food and probiotics.</p></caption><graphic xlink:href="fny291fig3"/></fig></sec></body><back><sec id="sec5"><title>FUNDING</title><p>This work was supported by Hans Werth&#x000e9;n Fonden, Sweden; Marine Biotechnology ERA-NET &#x02018;ThermoFactories&#x02019; (grant number 5178&#x02013;00003B); and the Novo Nordisk Foundation, Denmark.</p></sec><sec id="sec6"><title/><p>
<bold><italic>Conflict of interest.</italic></bold> None declared.</p></sec><ref-list><title>REFERENCES</title><ref id="bib1"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Jamal</surname><given-names>QMS</given-names></name><etal/></person-group>
<article-title>Antimicrobial potential of bacteriocins: In therapy, agriculture and food preservation</article-title>. <source>Int J Antimicrob Agents</source><year>2017</year>;<volume>49</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">27773497</pub-id></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Allain</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Aubry</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Natividad</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Engineering lactic acid bacteria and Bifidobacteria for mucosal delivery of health molecules</article-title>. <source>Biotechnol Lact Acid Bact Nov Appl Second Ed</source><year>2015</year>:<fpage>170</fpage>&#x02013;<lpage>90</lpage>.</mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Herrero</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Su&#x000e1;rez</surname><given-names>JE</given-names></name></person-group>
<article-title>The site-specific recombination system of the Lactobacillus Species Bacteriophage A2 integrates in Gram-positive and Gram-negative bacteria</article-title>. <source>Virology</source><year>1998</year>;<volume>250</volume>:<fpage>185</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">9770432</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Axel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zannini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Coffey</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ecofriendly control of potato late blight causative agent and the potential role of lactic acid bacteria: a review</article-title>. <source>Appl Microbiol Biotechnol</source><year>2012</year>;<volume>96</volume>:<fpage>37</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">22864968</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bachmann</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pronk</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Kleerebezem</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Evolutionary engineering to enhance starter culture performance in food fermentations</article-title>. <source>Curr Opin Biotechnol</source><year>2015</year>;<volume>32</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25269887</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Barrangou</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fremaux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Deveau</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>CRISPR provides acquired resistance against viruses in prokaryotes</article-title>. <source>Science</source><year>2007</year>;<volume>315</volume>:<fpage>1709</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17379808</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Berlec</surname><given-names>A</given-names></name>, <name name-style="western"><surname>&#x00160;krlec</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kocjan</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Single plasmid systems for inducible dual protein expression and for CRISPR-Cas9/CRISPRi gene regulation in lactic acid bacterium Lactococcus lactis/CRISPRi gene regulation in lactic acid bacterium <italic>Lactococcus lactis</italic></article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>1709</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">29374167</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bikard</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Samai</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system</article-title>. <source>Nucleic Acids Res</source><year>2013</year>;<volume>41</volume>:<fpage>7429</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">23761437</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Blokesch</surname><given-names>M</given-names></name></person-group>
<article-title>Natural competence for transformation</article-title>. <source>Curr Biol</source><year>2016</year>;<volume>26</volume>:<fpage>R1126</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">27825443</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bober</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Beisel</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>NU</given-names></name></person-group>
<article-title>Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications</article-title>. <source>Annu Rev Biomed Eng</source><year>2018</year>;<volume>20</volume>:<fpage>277</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">29528686</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Boguta</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Bringel</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Martinussen</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Screening of lactic acid bacteria for their potential as microbial cell factories for bioconversion of lignocellulosic feedstocks</article-title>. <source>Microb Cell Fact</source><year>2014</year>;<volume>13</volume>:<fpage>97</fpage>.<pub-id pub-id-type="pmid">24997803</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bosma</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Forster</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>AT</given-names></name></person-group>
<article-title>Lactobacilli and pediococci as versatile cell factories &#x02013; Evaluation of strain properties and genetic tools</article-title>. <source>Biotechnol Adv</source><year>2017</year>;<volume>35</volume>:<fpage>419</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">28396124</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bourdichon</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Casaregola</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Farrokh</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Food fermentations: Microorganisms with technological beneficial use</article-title>. <source>Int J Food Microbiol</source><year>2012</year>;<volume>154</volume>:<fpage>87</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">22257932</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bowater</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Doherty</surname><given-names>AJ</given-names></name></person-group>
<article-title>Making ends meet: Repairing breaks in bacterial DNA by non-homologous end-joining</article-title>. <source>PLoS Genet</source><year>2006</year>;<volume>2</volume>:<fpage>e8</fpage>.<pub-id pub-id-type="pmid">16518468</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bron</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Kleerebezem</surname><given-names>M</given-names></name></person-group>
<article-title>Lactic acid bacteria for delivery of endogenous or engineered therapeutic molecules</article-title>. <source>Front Microbiol</source><year>2018</year>;<volume>9</volume>, DOI:<pub-id pub-id-type="doi">10.3389/fmicb.2018.01821</pub-id>.</mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bron</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Marcelli</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Mulder</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Renaissance of traditional DNA transfer strategies for improvement of industrial lactic acid bacteria</article-title>. <source>Curr Opin Biotechnol</source><year>2019</year>;<volume>56</volume>:<fpage>61</fpage>&#x02013;<lpage>68</lpage>.</mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bron</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Meijer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bongers</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>Dynamics of competitive population abundance of <italic>Lactobacillus plantarum</italic> ivi gene mutants in faecal samples after passage through the gastrointestinal tract of mice</article-title>. <source>J Appl Microbiol</source><year>2007</year>;<volume>103</volume>:<fpage>1424</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">17953553</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brouns</surname><given-names>SJJ</given-names></name>, <name name-style="western"><surname>Jore</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Lundgren</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Small CRISPR RNAs guide antiviral defense in prokaryotes</article-title>. <source>Science</source><year>2008</year>;<volume>321</volume>:<fpage>960</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">18703739</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Br&#x000f8;ndsted</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hammer</surname><given-names>K</given-names></name></person-group>
<article-title>Use of the integration elements encoded by the temperate lactococcal bacteriophage TP901-1 to obtain chromosomal single-copy transcriptional fusions in <italic>Lactococcus lactis</italic></article-title>. <source>Appl Environ Microbiol</source><year>1999</year>;<volume>65</volume>:<fpage>960</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name></person-group>
<article-title>CRISPR plants now subject to tough GM laws in European Union</article-title>. <source>Nature</source><year>2018</year>;<volume>560</volume>:<fpage>16</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">30065322</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nielsen</surname><given-names>J</given-names></name></person-group>
<article-title>The impact of systems biology on bioprocessing</article-title>. <source>Trends Biotechnol</source><year>2017</year>;<volume>35</volume>:<fpage>1156</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">28987922</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Carvalho RDDO</collab>, <name name-style="western"><surname>do Carmo</surname><given-names>FLR</given-names></name>, <name name-style="western"><surname>de Oliveira Junior</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases: A focus on inflammatory bowel diseases and mucositis</article-title>. <source>Front Microbiol</source><year>2017</year>;<volume>8</volume>:<fpage>1</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="pmid">28197127</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>CTY</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Cameron</surname><given-names>DE</given-names></name><etal/></person-group> &#x0201c;<article-title>'Deadman' and 'Passcode' microbial kill switches for bacterial containment</article-title>. <source>Nat Chem Biol</source><year>2016</year>;<volume>12</volume>:<fpage>82</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">26641934</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vestergaard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Jensen</surname><given-names>TG</given-names></name><etal/></person-group>
<article-title>Finding the needle in the haystack - the use of microfluidic droplet technoloty to identify vitamin-secreting Lacic Acid Bacteria</article-title>. <source>mBio - Am Soc Microbiol</source><year>2017</year>;<volume>8</volume>:<fpage>e00526</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>Court of Justice of the European Union</collab></person-group>
<comment>PRESS RELEASE No 111/18: Organisms obtained by mutagenesis are GMOs and are, in principle, subject to the obligations laid down by the GMO Directive</comment>
<source>Judgm Case C-528/16</source><year>2018</year>:<fpage>2001</fpage>&#x02013;<lpage>2</lpage>.</mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Crawley</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Henriksen</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Stout</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli</article-title>. <source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>11544</fpage>.<pub-id pub-id-type="pmid">30068963</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Csutak</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Sarbu</surname><given-names>I.</given-names></name></person-group>
<source>Chapter 6 - Genetically Modified Microorganisms: Harmful or Helpful</source>? <publisher-name>Elsevier Inc</publisher-name>, <comment>Cambridge, Massachusetts, USA</comment>, <year>2018</year>.</mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dahmane</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Robert</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Deschamps</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Impact of Cell Surface Molecules on Conjugative Transfer of the Integrative and Conjugative Element ICE St3 of Streptococcus thermophilus</article-title>. <comment>Kivisaar M (ed.)</comment>
<source>Appl Environ Microbiol</source><year>2017</year>;<volume>84</volume>, DOI: <pub-id pub-id-type="doi">10.1128/AEM.02109-17</pub-id>.</mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Darajati</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Pratiwi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Herwinda</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Nagoya Protocol</article-title>. <source>Diversity</source><year>2013</year>;<volume>12</volume>:<fpage>1</fpage>&#x02013;<lpage>320</lpage>.</mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Radziejwoski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Toussaint</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Natural DNA transformation is functional in <italic>Lactococcus lactis</italic> subsp. <italic>cremoris</italic> KW2. Vieille C (ed.)</article-title>. <source>Appl Environ Microbiol</source><year>2017</year>;<volume>83</volume>, DOI: <pub-id pub-id-type="doi">10.1128/AEM.01074-17</pub-id>.</mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Derkx</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Janzen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>S&#x000f8;rensen</surname><given-names>KI</given-names></name><etal/></person-group>
<article-title>The art of strain improvement of industrial lactic acid bacteria without the use of recombinant DNA technology</article-title>. <source>Microb Cell Fact</source><year>2014</year>;<volume>13</volume>:<fpage>S5</fpage>.<pub-id pub-id-type="pmid">25186244</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dronkers</surname><given-names>TMG</given-names></name>, <name name-style="western"><surname>Krist</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Van Overveld</surname><given-names>FJ</given-names></name><etal/></person-group>
<article-title>The ascent of the blessed: Regulatory issues on health effects and health claims for probiotics in Europe and the rest of the world</article-title>. <source>Benef Microbes</source><year>2018</year>;<volume>9</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">29376756</pub-id></mixed-citation></ref><ref id="bib33"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Duarte</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Barbier</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Schaerli</surname><given-names>Y</given-names></name></person-group>
<article-title>Bacterial microcolonies in gel beads for high-throughput screening of libraries in synthetic biology</article-title>. <source>ACS Synth Biol</source><year>2017</year>;<volume>6</volume>:<fpage>1988</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">28803463</pub-id></mixed-citation></ref><ref id="bib34"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dupuis</surname><given-names>M&#x000c8;</given-names></name>, <name name-style="western"><surname>Villion</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Magad&#x000e1;n</surname><given-names>AH</given-names></name><etal/></person-group>
<article-title>CRISPR-Cas and restriction-modification systems are compatible and increase phage resistance</article-title>. <source>Nat Commun</source><year>2013</year>;<volume>4</volume>:<fpage>1</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="bib35"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Durrer</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Hunt von Herbing</surname><given-names>I</given-names></name></person-group>
<article-title>Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU</article-title>. <source>PLoS ONE</source><year>2017</year>;<volume>12</volume>:<fpage>e0176286</fpage>.<pub-id pub-id-type="pmid">28520731</pub-id></mixed-citation></ref><ref id="bib36"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Eid</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alshareef</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mahfouz</surname><given-names>MM</given-names></name></person-group>
<article-title>CRISPR base editors: Genome editing without double-stranded breaks</article-title>. <source>Biochem J</source><year>2018</year>;<volume>475</volume>:<fpage>1955</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">29891532</pub-id></mixed-citation></ref><ref id="bib37"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van der Els</surname><given-names>S</given-names></name>, <name name-style="western"><surname>James</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Kleerebezem</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Versatile Cas9-Driven Subpopulation Selection Toolbox for Lactococcus lactis</article-title>. <source>Appl Environ Microbiol</source><year>2018</year>:<comment>AEM.02752-17</comment>.</mixed-citation></ref><ref id="bib38"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Emanuel</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Moffitt</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Zhuang</surname><given-names>X</given-names></name></person-group>
<article-title>High-throughput, image-based screening of pooled genetic-variant libraries</article-title>. <source>Nat Meth</source><year>2017</year>;<volume>14</volume>:<fpage>1159</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="bib39"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><collab>FDA</collab></person-group>
<article-title>Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat <italic>Clostridium difficile</italic> infection not responsive to standard therapies</article-title>. <source>US Food and Drug Administration Fed Regist</source><year>2016</year>;<volume>78</volume>:<fpage>42965</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="bib40"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fears</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ter Meulen</surname><given-names>V</given-names></name></person-group>
<article-title>How should the applications of genome editing be assessed and regulated?</article-title><source>Elife</source><year>2017</year>;<volume>6</volume>, DOI: <pub-id pub-id-type="doi">10.7554/eLife.26295</pub-id>.</mixed-citation></ref><ref id="bib41"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gajbhiye</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Kapadnis</surname><given-names>BP</given-names></name></person-group>
<article-title>Antifungal-activity-producing lactic acid bacteria as biocontrol agents in plants</article-title>. <source>Biocontrol Sci Technol</source><year>2016</year>;<volume>26</volume>:<fpage>1451</fpage>&#x02013;<lpage>70</lpage>.</mixed-citation></ref><ref id="bib42"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gardan</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Besset</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Guillot</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The oligopeptide transport system is essential for the development of natural competence in <italic>Streptococcus thermophilus</italic> strain LMD-9</article-title>. <source>J Bacteriol</source><year>2009</year>;<volume>191</volume>:<fpage>4647</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">19447907</pub-id></mixed-citation></ref><ref id="bib43"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gaspar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Vinga</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>From physiology to systems metabolic engineering for the production of biochemicals by lactic acid bacteria</article-title>. <source>Biotechnol Adv</source><year>2013</year>;<volume>31</volume>:<fpage>764</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">23567148</pub-id></mixed-citation></ref><ref id="bib44"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Glanville</surname><given-names>J</given-names></name>, <name name-style="western"><surname>King</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guarner</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>A review of the systematic review process and its applicability for use in evaluating evidence for health claims on probiotic foods in the European Union</article-title>. <source>Nutr J</source><year>2015</year>;<volume>14</volume>:<fpage>16</fpage>.<pub-id pub-id-type="pmid">25889449</pub-id></mixed-citation></ref><ref id="bib45"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grath</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>van Sinderen</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>GF</given-names></name></person-group>
<article-title>Bacteriophage-derived genetic tools for use in lactic acid bacteria</article-title>. <source>Int Dairy J</source><year>2002</year>;<volume>12</volume>:<fpage>3</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="bib46"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Guinane</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Crispie</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cotter</surname><given-names>PD</given-names></name></person-group>
<source>Value of Microbial Genome Sequencing for Probiotic Strain Identification and Characterization: Promises and Pitfalls</source>. <publisher-name>Elsevier Inc., Amsterdam, NL</publisher-name>, <year>2016</year>.</mixed-citation></ref><ref id="bib47"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hatti-Kaul</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dishisha</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Lactic acid bacteria: From starter cultures to producers of chemicals</article-title>. <source>FEMS Microbiol Lett</source><year>2018</year>;<volume>365</volume>.</mixed-citation></ref><ref id="bib48"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>IY</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name><etal/></person-group>
<article-title>Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria</article-title>. <source>Drug Resist Updat</source><year>2016</year>;<volume>27</volume>:<fpage>59</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">27449598</pub-id></mixed-citation></ref><ref id="bib49"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>IY</given-names></name>, <name name-style="western"><surname>Koh</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Engineered probiotic <italic>Escherichia coli</italic> can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models</article-title>. <source>Nat Comms</source><year>2017</year>;<volume>8</volume>:<fpage>15028</fpage>.</mixed-citation></ref><ref id="bib50"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Intelligence</surname><given-names>Mordor</given-names></name></person-group>
<source>Global Fermented Foods &#x00026; Drinks Market - Growth, Trends and Forecast (2018 - 2023)</source>. <comment>Mordor Intelligence, Hyderabad, India</comment>, <year>2018</year>.</mixed-citation></ref><ref id="bib51"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Jensen</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Solem</surname><given-names>C</given-names></name><etal/></person-group>
<comment>A bacterial cell factory for efficient production of ethanol from whey</comment>
<year>2017</year>:<comment>WO2017144672A1</comment>.</mixed-citation></ref><ref id="bib52"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name></person-group>
<source>et al</source>. <article-title>CRISPR-Cpf1 assisted genome editing of <italic>Corynebacterium glutamicum</italic></article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>:<fpage>15179</fpage>.</mixed-citation></ref><ref id="bib53"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Joergensen</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Regueira</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>Kobmann</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Bacterial mutants with improved transformation efficiency</article-title>. <year>2013</year>:<comment>WO2013173711A1</comment>.</mixed-citation></ref><ref id="bib54"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Johansen</surname><given-names>E</given-names></name></person-group>
<article-title>Future access and improvement of industrial lactic acid bacteria cultures</article-title>. <source>Microb Cell Fact</source><year>2017</year>;<volume>16</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">28049473</pub-id></mixed-citation></ref><ref id="bib55"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Johansen</surname><given-names>E</given-names></name></person-group>
<article-title>Use of natural selection and evolution to develop new starter cultures for fermented foods</article-title>. <source>Annual Review of Food Science and Technology</source><year>2018</year>;<volume>9</volume>:<fpage>411</fpage>&#x02013;<lpage>28</lpage>.</mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kala&#x0010d;</surname><given-names>P</given-names></name></person-group>
<article-title>The effects of silage feeding on some sensory and health attributes of cow's milk: A review</article-title>. <source>Food Chem</source><year>2011</year>;<volume>125</volume>:<fpage>307</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="bib57"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YB</given-names></name>, <name name-style="western"><surname>Komor</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions</article-title>. <source>Nat Biotechnol</source><year>2017</year>;<volume>35</volume>:<fpage>371</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">28191901</pub-id></mixed-citation></ref><ref id="bib58"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Konappa</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Maria</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Uzma</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Lactic acid bacteria mediated induction of defense enzymes to enhance the resistance in tomato against <italic>Ralstonia solanacearum</italic> causing bacterial wilt</article-title>. <source>Scientia Horticulturae</source><year>2016</year>;<volume>207</volume>:<fpage>183</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="bib59"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Koonin E</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Makarova</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name></person-group>
<article-title>Diversity, classification and evolution of CRISPR-Cas systems</article-title>. <source>Curr Opin Microbiol</source><year>2017</year>;<volume>37</volume>:<fpage>67</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">28605718</pub-id></mixed-citation></ref><ref id="bib60"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kullen</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Klaenhammer</surname><given-names>TR</given-names></name></person-group>
<article-title>Genetic modification of intestinal lactobacilli and bifidobacteria</article-title>. <source>Curr Issues Mol Biol</source><year>2000</year>;<volume>2</volume>:<fpage>41</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="pmid">11471563</pub-id></mixed-citation></ref><ref id="bib61"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lamont</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Wilkins</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bywater-Ekeg&#x000e4;rd</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>From yogurt to yield: Potential applications of lactic acid bacteria in plant production</article-title>. <source>Soil Biol Biochem</source><year>2017</year>;<volume>111</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="bib62"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Landete</surname><given-names>JM</given-names></name></person-group>
<article-title>A review of food-grade vectors in lactic acid bacteria: From the laboratory to their application</article-title>. <source>Crit Rev Biotechnol</source><year>2017</year>;<volume>37</volume>:<fpage>296</fpage>&#x02013;<lpage>308</lpage>.<pub-id pub-id-type="pmid">26918754</pub-id></mixed-citation></ref><ref id="bib63"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Landete</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Arqu&#x000e9;s</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>&#x000c1;</surname><given-names>Peirot&#x000e9;n</given-names></name><etal/></person-group>
<article-title>An improved method for the electrotransformation of lactic acid bacteria: A comparative survey</article-title>. <source>J Microbiol Methods</source><year>2014</year>;<volume>105</volume>:<fpage>130</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">25086179</pub-id></mixed-citation></ref><ref id="bib64"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lebeer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bron</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Marco</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Identification of probiotic effector molecules: Present state and future perspectives</article-title>. <source>Curr Opin Biotechnol</source><year>2018</year>;<volume>49</volume>:<fpage>217</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">29153882</pub-id></mixed-citation></ref><ref id="bib65"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Leenay</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Vento</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Shah</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Genome editing with CRISPR-Cas9 in Lactobacillus plantarum revealed that editing outcomes can vary across strains and between methods</article-title>. <source>Biotechnol J</source><year>2018</year>:<fpage>1700583</fpage>.</mixed-citation></ref><ref id="bib66"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Harnessing Type I and Type III CRISPR-Cas systems for genome editing</article-title>. <source>Nucleic Acids Res</source><year>2016</year>;<volume>44</volume>:<fpage>e34</fpage>.<pub-id pub-id-type="pmid">26467477</pub-id></mixed-citation></ref><ref id="bib67"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dantoft</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>W&#x000fc;rtz</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>A novel cell factory for efficient production of ethanol from dairy waste</article-title>. <source>Biotechnol Biofuels</source><year>2016</year>;<volume>9</volume>:<fpage>33</fpage>.<pub-id pub-id-type="pmid">26925162</pub-id></mixed-citation></ref><ref id="bib68"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Longwell</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Labanieh</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cochran</surname><given-names>JR</given-names></name></person-group>
<article-title>High-throughput screening technologies for enzyme engineering</article-title>. <source>Curr Opin Biotechnol</source><year>2017</year>;<volume>48</volume>:<fpage>196</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">28624724</pub-id></mixed-citation></ref><ref id="bib69"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lubkowicz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>IY</given-names></name><etal/></person-group>
<article-title>Reprogramming probiotic Lactobacillus reuteri as a biosensor for Staphylococcus aureus derived AIP-I detection</article-title>. <source>ACS Synth Biol</source><year>2018</year>;<volume>7</volume>:<fpage>1229</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">29652493</pub-id></mixed-citation></ref><ref id="bib70"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Mullis</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Leenay</surname><given-names>RT</given-names></name><etal/></person-group>
<article-title>Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression</article-title>. <source>Nucleic Acids Res</source><year>2015</year>;<volume>43</volume>:<fpage>674</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">25326321</pub-id></mixed-citation></ref><ref id="bib71"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Field</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rea</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Bacteriocin-antimicrobial synergy: A medical and food perspective</article-title>. <source>Front Microbiol</source><year>2017</year>;<volume>8</volume>:<fpage>1205</fpage>.<pub-id pub-id-type="pmid">28706513</pub-id></mixed-citation></ref><ref id="bib72"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Matthews</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Grimaldi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Lactic acid bacteria as a potential source of enzymes for use in vinification</article-title>. <source>Appl Environ Microbiol</source><year>2004</year>;<volume>70</volume>:<fpage>5715</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">15466506</pub-id></mixed-citation></ref><ref id="bib73"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mays</surname><given-names>ZJ</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>NU</given-names></name></person-group>
<article-title>Synthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics</article-title>. <source>Curr Opin Biotechnol</source><year>2018</year>;<volume>53</volume>:<fpage>224</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">29550614</pub-id></mixed-citation></ref><ref id="bib74"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mazzoli</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bosco</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Mizrahi</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Towards lactic acid bacteria-based biorefineries</article-title>. <source>Biotechnol Adv</source><year>2014</year>;<volume>32</volume>:<fpage>1216</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">25087936</pub-id></mixed-citation></ref><ref id="bib75"><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Meacher</surname><given-names>M</given-names></name></person-group>
<article-title>The genetically modified organisms (contained use) regulations 2000</article-title>. <year>2000</year>
<comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.legislation.gov.uk/uksi">http://www.legislation.gov.uk/uksi</ext-link></comment>.</mixed-citation></ref><ref id="bib76"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mercenier</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chassy</surname><given-names>BM</given-names></name></person-group>
<article-title>Strategies for the development of bacterial transformation systems</article-title>. <source>Biochimie</source><year>1988</year>;<volume>70</volume>:<fpage>503</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">3139069</pub-id></mixed-citation></ref><ref id="bib77"><mixed-citation publication-type="other">
<comment>Research and Markets. Microbiome Therapeutics and Diagnostics Market (2nd edition), 2017&#x02013;2030. 2017. Report ID 4377904</comment>.</mixed-citation></ref><ref id="bib78"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Minervini</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Celano</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lattanzi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Lactic acid bacteria in durum wheat flour are endophytic components of the plant during its entire life cycle</article-title>. <source>Appl Environ Microbiol</source><year>2015</year>;<volume>81</volume>:<fpage>6736</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">26187970</pub-id></mixed-citation></ref><ref id="bib79"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Moreno De Leblanc</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Del Carmen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chatel</surname><given-names>JM</given-names></name><etal/></person-group>
<article-title>Current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models</article-title>. <source>Gastroenterol Res Prac</source><year>2015</year>;<volume>2015</volume>, DOI: <pub-id pub-id-type="doi">10.1155/2015/146972</pub-id>.</mixed-citation></ref><ref id="bib80"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mougiakos</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bosma</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Ganguly</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Hijacking CRISPR-Cas for high-throughput bacterial metabolic engineering: advances and prospects</article-title>. <source>Curr Opin Biotechnol</source><year>2018</year>;<volume>50</volume>:<fpage>146</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="pmid">29414054</pub-id></mixed-citation></ref><ref id="bib81"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mougiakos</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Bosma</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>de Vos</surname><given-names>WM</given-names></name><etal/></person-group>
<article-title>Next generation prokaryotic engineering: The CRISPR-Cas toolkit</article-title>. <source>Trends Biotechnol</source><year>2016</year>;<volume>34</volume>:<fpage>575</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">26944793</pub-id></mixed-citation></ref><ref id="bib82"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mougiakos</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Mohanraju</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bosma</surname><given-names>EF</given-names></name><etal/></person-group>
<article-title>Characterizing a thermostable Cas9 for bacterial genome editing and silencing</article-title>. <source>Nat Commun</source><year>2017</year>;<volume>8</volume>, DOI: <pub-id pub-id-type="doi">10.1038/s41467-017-01591-4</pub-id>.</mixed-citation></ref><ref id="bib83"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mulder</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wels</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kuipers</surname><given-names>OP</given-names></name><etal/></person-group>
<article-title>Unleashing natural competence in <italic>Lactococcus lactis</italic> by induction of the competence regulator ComX</article-title>. <source>Appl Environ Microbiol</source><year>2017</year>;<volume>83</volume>:<fpage>e01320</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="bib84"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Muschiol</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balaban</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Normark</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Uptake of extracellular DNA: Competence induced pili in natural transformation of Streptococcus pneumoniae</article-title>. <source>BioEssays</source><year>2015</year>;<volume>37</volume>:<fpage>426</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">25640084</pub-id></mixed-citation></ref><ref id="bib85"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nakade</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sakuma</surname><given-names>T</given-names></name></person-group>
<article-title>Cas9, Cpf1 and C2c1/2/3?What's next?</article-title>? <source>Bioengineered</source><year>2017</year>;<volume>8</volume>:<fpage>265</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">28140746</pub-id></mixed-citation></ref><ref id="bib86"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Van Pijkeren</surname><given-names>JP</given-names></name></person-group>
<article-title>CRISPR&#x02013;Cas9-assisted recombineering in Lactobacillus reuteri</article-title>. <source>Nucleic Acids Res</source><year>2014</year>;<volume>42</volume>:<fpage>e131-</fpage>.<pub-id pub-id-type="pmid">25074379</pub-id></mixed-citation></ref><ref id="bib87"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ortiz-Velez</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ortiz-Villalobos</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Schulman</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Genome alterations associated with improved transformation efficiency in <italic>Lactobacillus reuteri</italic></article-title>. <source>Microb Cell Fact</source><year>2018</year>;<volume>17</volume>:<fpage>138</fpage>.<pub-id pub-id-type="pmid">30176942</pub-id></mixed-citation></ref><ref id="bib88"><mixed-citation publication-type="book">
<person-group person-group-type="author"><collab>Palsson BO. Model-Driven Discovery</collab></person-group>
<source>Systems Biology</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, <year>2015</year>, <fpage>407</fpage>&#x02013;<lpage>21</lpage>.</mixed-citation></ref><ref id="bib89"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Patnaik</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Louie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gavrilovic</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Genome shuffling of <italic>Lactobacillus</italic> for improved acid tolerance</article-title>. <source>Nat Biotechnol</source><year>2002</year>;<volume>20</volume>:<fpage>707</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">12089556</pub-id></mixed-citation></ref><ref id="bib90"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Iversen</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>S&#x000f8;rensen</surname><given-names>KI</given-names></name><etal/></person-group>
<article-title>The long and winding road from the research laboratory to industrial applications of lactic acid bacteria</article-title>. <source>FEMS Microbiol Rev</source><year>2005</year>;<volume>29</volume>:<fpage>611</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">15935510</pub-id></mixed-citation></ref><ref id="bib91"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pereira</surname><given-names>GV</given-names></name>, <name name-style="western"><surname>de</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Soccol</surname><given-names>VT</given-names></name>, <name name-style="western"><surname>Soccol</surname><given-names>CR</given-names></name></person-group>
<article-title>Current state of research on cocoa and coffee fermentations</article-title>. <source>Curr Opin Food Sci</source><year>2016</year>;<volume>7</volume>:<fpage>50</fpage>&#x02013;<lpage>57</lpage>.</mixed-citation></ref><ref id="bib92"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Perna</surname><given-names>FM</given-names></name>, <name name-style="western"><surname>Ricci</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Scilimati</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Cheap and environmentally sustainable stereoselective arylketones reduction by <italic>Lactobacillus reuteri</italic> whole cells</article-title>. <source>J Mol Catal B: Enzymatic</source><year>2016</year>;<volume>124</volume>:<fpage>29</fpage>&#x02013;<lpage>37</lpage>.</mixed-citation></ref><ref id="bib93"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Colavin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>A Comprehensive, CRISPR-based functional analysis of essential genes in bacteria</article-title>. <source>Cell</source><year>2016</year>;<volume>165</volume>:<fpage>1493</fpage>&#x02013;<lpage>506</lpage>.<pub-id pub-id-type="pmid">27238023</pub-id></mixed-citation></ref><ref id="bib94"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Pijkeren</surname><given-names>J-P</given-names></name>, <name name-style="western"><surname>Barrangou</surname><given-names>R</given-names></name></person-group>
<article-title>Genome editing of food-grade lactobacilli to develop therapeutic probiotics</article-title>. <source>Microbiol Spectr</source><year>2017</year>;<volume>5</volume>, DOI: <pub-id pub-id-type="doi">10.1128/microbiolspec.BAD-0013-2016</pub-id>.</mixed-citation></ref><ref id="bib95"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Pijkeren</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Britton</surname><given-names>RA</given-names></name></person-group>
<article-title>Precision genome engineering in lactic acid bacteria</article-title>. <source>Microb Cell Fact</source><year>2014</year>;<volume>13</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">24387764</pub-id></mixed-citation></ref><ref id="bib96"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Pijkeren</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Britton</surname><given-names>RA</given-names></name></person-group>
<article-title>High efficiency recombineering in lactic acid bacteria</article-title>. <source>Nucleic Acids Res</source><year>2012</year>;<volume>40</volume>:<fpage>e76</fpage>.<pub-id pub-id-type="pmid">22328729</pub-id></mixed-citation></ref><ref id="bib97"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pines</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Freed</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Winkler</surname><given-names>JD</given-names></name><etal/></person-group>
<article-title>Bacterial recombineering: Genome engineering via phage-based homologous recombination</article-title>. <source>ACS Synth Biol</source><year>2015</year>;<volume>4</volume>:<fpage>1176</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">25856528</pub-id></mixed-citation></ref><ref id="bib98"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Prajapati</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Nair</surname><given-names>BM</given-names></name></person-group>
<article-title>The history of fermented foods</article-title>. <source>In: Farnworth, ER (Ed) Fermented Functional Foods</source>, CRC Press, Boca Raton, Florida, USA, <year>2003</year>, <fpage>1</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="bib99"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pursey</surname><given-names>E</given-names></name>, <name name-style="western"><surname>S&#x000fc;nderhauf</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gaze</surname><given-names>WH</given-names></name><etal/></person-group>
<article-title>CRISPR-Cas antimicrobials: Challenges and future prospects</article-title>. <source>PLoS Pathog</source><year>2018</year>;<volume>14</volume>:<fpage>e1006990</fpage>.<pub-id pub-id-type="pmid">29902258</pub-id></mixed-citation></ref><ref id="bib100"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Larson</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Gilbert</surname><given-names>LA</given-names></name><etal/></person-group>
<article-title>Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression</article-title>. <source>Cell</source><year>2013</year>;<volume>152</volume>:<fpage>1173</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">23452860</pub-id></mixed-citation></ref><ref id="bib101"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rath</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Amlinger</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hoekzema</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Efficient programmable gene silencing by Cascade</article-title>. <source>Nucleic Acids Res</source><year>2015</year>;<volume>43</volume>:<fpage>237</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25435544</pub-id></mixed-citation></ref><ref id="bib102"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rau</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Zeidan</surname><given-names>AA</given-names></name></person-group>
<article-title>Constraint-based modeling in microbial food biotechnology</article-title>. <source>Biochem Soc Trans</source><year>2018</year>;<volume>0</volume>:<fpage>BST20170268</fpage>.</mixed-citation></ref><ref id="bib103"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>G</given-names></name></person-group>
<article-title>The development of probiotics for women's health</article-title>. <source>Can J Microbiol</source><year>2017</year>;<volume>63</volume>:<fpage>269</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">28177795</pub-id></mixed-citation></ref><ref id="bib104"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rousset</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Cui</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Siouve</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Genome-wide CRISPR-dCas9 screens in <italic>E. coli</italic> identify essential genes and phage host factors</article-title>. <comment>Blokesch M (ed.)</comment>
<source>PLOS Genet</source><year>2018</year>;<volume>14</volume>:<fpage>e1007749</fpage>.<pub-id pub-id-type="pmid">30403660</pub-id></mixed-citation></ref><ref id="bib105"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Salvetti</surname><given-names>E</given-names></name>, <name name-style="western"><surname>O&#x02019;Toole</surname><given-names>PW</given-names></name></person-group>
<article-title>When regulation challenges innovation: The case of the genus <italic>Lactobacillus</italic></article-title>. <source>Trends Food Sci Technol</source><year>2017</year>;<volume>66</volume>:<fpage>187</fpage>&#x02013;<lpage>94</lpage>.</mixed-citation></ref><ref id="bib106"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sauer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Russmayer</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Grabherr</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The efficient clade: Lactic acid bacteria for industrial chemical production</article-title>. <source>Trends Biotechnol</source><year>2017</year>;<volume>35</volume>:<fpage>756</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">28549804</pub-id></mixed-citation></ref><ref id="bib107"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Selle</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Klaenhammer</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Barrangou</surname><given-names>R</given-names></name></person-group>
<article-title>CRISPR-based screening of genomic island excision events in bacteria</article-title>. <source>Proc Natl Acad Sci USA</source><year>2015</year>;<volume>112</volume>:<fpage>8076</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26080436</pub-id></mixed-citation></ref><ref id="bib108"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sheth</surname><given-names>RU</given-names></name>, <name name-style="western"><surname>Cabral</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>SP</given-names></name><etal/></person-group>
<article-title>Manipulating bacterial communities by in situ microbiome engineering</article-title>. <source>Trends Genet</source><year>2016</year>;<volume>32</volume>:<fpage>189</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">26916078</pub-id></mixed-citation></ref><ref id="bib109"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Xiong</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>CRISPR-Cas9 D10A Nickase-Assisted Genome Editing in Lactobacillus casei</article-title>. <source>Appl Environ Microbiol</source><year>2017</year>:<comment>AEM.01259-17</comment>.</mixed-citation></ref><ref id="bib110"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Spath</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Heinl</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Grabherr</surname><given-names>R</given-names></name></person-group>
<article-title>&#x0201c;Direct cloning in Lactobacillus plantarum: Electroporation with non-methylated plasmid DNA enhances transformation efficiency and makes shuttle vectors obsolete&#x0201d;</article-title>. <source>Microb Cell Fact</source><year>2012</year>;<volume>11</volume>:<fpage>1</fpage>.<pub-id pub-id-type="pmid">22214286</pub-id></mixed-citation></ref><ref id="bib111"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Ste Croix</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vacca</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kwun</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Phase-variable methylation and epigenetic regulation by type I restriction&#x02013;modification systems</article-title>. <source>FEMS Microbiol Rev</source><year>2017</year>;<volume>41</volume>:<fpage>S3</fpage>&#x02013;<lpage>S15</lpage>.<pub-id pub-id-type="pmid">28830092</pub-id></mixed-citation></ref><ref id="bib112"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stefanovic</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Fitzgerald</surname><given-names>G</given-names></name>, <name name-style="western"><surname>McAuliffe</surname><given-names>O</given-names></name></person-group>
<article-title>Advances in the genomics and metabolomics of dairy lactobacilli: A review</article-title>. <source>Food Microbiol</source><year>2017</year>;<volume>61</volume>:<fpage>33</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">27697167</pub-id></mixed-citation></ref><ref id="bib113"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Stuer-Lauridsen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Janzen</surname><given-names>T</given-names></name></person-group>
<article-title>Bacteriophage resistant lactic acid bacteria</article-title>. <source>Eur Pat Specif</source><year>2006</year>;<volume>EP 1 8383</volume>:<fpage>1</fpage>&#x02013;<lpage>17</lpage>.</mixed-citation></ref><ref id="bib114"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>HMB</given-names></name>, <name name-style="western"><surname>McCann</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Expanding the biotechnology potential of lactobacilli through comparative genomics of 213 strains and associated genera</article-title>. <source>Nat Commun</source><year>2015</year>;<volume>6</volume>:<fpage>8322</fpage>.<pub-id pub-id-type="pmid">26415554</pub-id></mixed-citation></ref><ref id="bib115"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sybesma</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Hugenholtz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Vos</surname><given-names>WM</given-names></name><etal/></person-group>
<article-title>Safe use of genetically modified lactic acid bacteria in food. Bridging the gap between consumers, green groups, and industry</article-title>. <source>Electron J Biotechnol</source><year>2006</year>;<volume>9</volume>:<fpage>0</fpage>&#x02013;<lpage>0</lpage>.</mixed-citation></ref><ref id="bib116"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Syngai</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Gopi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bharali</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Probiotics - the versatile functional food ingredients</article-title>. <source>J Food Sci Technol</source><year>2016</year>;<volume>53</volume>:<fpage>921</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27162372</pub-id></mixed-citation></ref><ref id="bib117"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Teresa Alegre</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carmen Rodr&#x000ed;guez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mesas</surname><given-names>JM</given-names></name></person-group>
<article-title>Transformation of Lactobacillus plantarum by electroporation with in vitro modified plasmid DNA</article-title>. <source>FEMS Microbiol Lett</source><year>2004</year>;<volume>241</volume>:<fpage>73</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">15556712</pub-id></mixed-citation></ref><ref id="bib118"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vasu</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nagaraja</surname><given-names>V</given-names></name></person-group>
<article-title>Diverse functions of restriction-modification systems in addition to cellular defense</article-title>. <source>Microbiol Molecular Biol Rev</source><year>2013</year>;<volume>77</volume>:<fpage>53</fpage>&#x02013;<lpage>72</lpage>.</mixed-citation></ref><ref id="bib119"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Verstrepen</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Chambers</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Pretorius</surname><given-names>IS</given-names></name></person-group>
<article-title>The development of superior yeast strains for the food and beverage industries: Challenges, opportunities and potential benefits</article-title>. In: Querol A., Fleet G. (eds). <source>Yeasts in Food and Beverages</source>. <comment>Berlin: Springer</comment>, <year>2006</year>, <fpage>399</fpage>&#x02013;<lpage>444</lpage>.</mixed-citation></ref><ref id="bib120"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Vos</surname><given-names>WM</given-names></name></person-group>
<article-title>Safe and sustainable systems for food-grade fermentations by genetically modified lactic acid bacteria</article-title>. <source>Int Dairy J</source><year>1999</year>;<volume>9</volume>:<fpage>3</fpage>&#x02013;<lpage>10</lpage>.</mixed-citation></ref><ref id="bib121"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Vos</surname><given-names>WM</given-names></name></person-group>
<article-title>Systems solutions by lactic acid bacteria: From paradigms to practice</article-title>. <source>Microb Cell Fact</source><year>2011</year>;<volume>10</volume>:<fpage>S2</fpage>.<pub-id pub-id-type="pmid">21995776</pub-id></mixed-citation></ref><ref id="bib122"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>De Vuyst</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Weckx</surname><given-names>S</given-names></name></person-group>
<article-title>The cocoa bean fermentation process: From ecosystem analysis to starter culture development</article-title>. <source>J Appl Microbiol</source><year>2016</year>;<volume>121</volume>:<fpage>5</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">26743883</pub-id></mixed-citation></ref><ref id="bib123"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>V&#x000e5;gesj&#x000f6;</surname><given-names>E</given-names></name>, <name name-style="western"><surname>&#x000d6;hnstedt</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Mortier</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Accelerated wound healing in mice by on-site production and delivery of CXCL12 by transformed lactic acid bacteria</article-title>. <source>Proc Natl Acad Sci</source><year>2018</year>;<volume>115</volume>:<fpage>201716580</fpage>.</mixed-citation></ref><ref id="bib124"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Crispie</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Claesson</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Translating omics to food microbiology</article-title>. <source>Ann Rev Food Sci Technol</source><year>2017</year>;<volume>8</volume>:<fpage>113</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">28125344</pub-id></mixed-citation></ref><ref id="bib125"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Lactic acid bacteria as mucosal delivery vehicles: A realistic therapeutic option</article-title>. <source>Appl Microbiol Biotechnol</source><year>2016</year>;<volume>100</volume>:<fpage>5691</fpage>&#x02013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">27154346</pub-id></mixed-citation></ref><ref id="bib126"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wegmann</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Carvalho</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Stocks</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>2294</fpage>.<pub-id pub-id-type="pmid">28536456</pub-id></mixed-citation></ref><ref id="bib127"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Coupling the recombineering to Cre-lox system enables simplified large-scale genome deletion in <italic>Lactobacillus casei</italic></article-title>. <source>Microb Cell Fact</source><year>2018</year>;<volume>17</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>.<pub-id pub-id-type="pmid">29306327</pub-id></mixed-citation></ref><ref id="bib128"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>Q</given-names></name></person-group>
<article-title>Prophage recombinases-mediated genome engineering in <italic>Lactobacillus plantarum</italic></article-title>. <source>Microb Cell Fact</source><year>2015</year>;<volume>14</volume>:<fpage>154</fpage>.<pub-id pub-id-type="pmid">26438232</pub-id></mixed-citation></ref><ref id="bib129"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>S-C</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C-H</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>CT</given-names></name><etal/></person-group>
<article-title>Antibacterial activities of bacteriocins: Application in foods and pharmaceuticals</article-title>. <source>Front Microbiol</source><year>2014</year>;<volume>5</volume>:<fpage>241</fpage>. <pub-id pub-id-type="pmid">24904554</pub-id></mixed-citation></ref><ref id="bib130"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zeidan</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Poulsen</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Janzen</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Polysaccharide production by lactic acid bacteria: From genes to industrial applications</article-title>. <source>FEMS Microbiol Rev</source><year>2017</year>;<volume>41</volume>:<fpage>S168</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">28830087</pub-id></mixed-citation></ref><ref id="bib131"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zerfa&#x000df;</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Soyer</surname><given-names>OS</given-names></name></person-group>
<article-title>Engineering microbial communities using thermodynamic principles and electrical interfaces</article-title>. <source>Curr Opin Biotechnol</source><year>2018</year>;<volume>50</volume>:<fpage>121</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29268107</pub-id></mixed-citation></ref><ref id="bib132"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion</article-title>. <source>Commun Biol</source><year>2018</year>;<volume>1</volume>:<fpage>32</fpage>.<pub-id pub-id-type="pmid">30271918</pub-id></mixed-citation></ref></ref-list></back></article>